Julie Forman-Kay is program head in molecular medicine at the Hospital for Sick Children in Toronto, Canada. She received her B.Sc. in chemistry from the Massachusetts Institute of Technology and her Ph.D. in molecular biophysics andd biochemistry from Yale University. The major focus of her lab is to provide biological insights into how dynamic properties of proteins are related to function and methodological tools to enable better understanding of dynamic and disordered states. Most recently, her lab has probed the biophysics of protein phase separation and how it regulates cellular condensates and biological function.
Julie Forman-Kay
Program head
Hospital for Sick Children
From this contributor
How microscopic ‘condensates’ in cells might contribute to autism
A controversial idea about how cells compartmentalize their contents into droplets — like beads of oil in water — could be key to understanding autism, says Julie Forman-Kay.
How microscopic ‘condensates’ in cells might contribute to autism
By
Angie Voyles Askham
23 February 2021 | 7 min read
Explore more from The Transmitter
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
By
Ashley Juavinett
30 March 2026 | 8 min read
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
By
Dalmeet Singh Chawla
27 March 2026 | 5 min read
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
By
Claudia López Lloreda
26 March 2026 | 4 min read